Rise Therapeutics Granted a Small Business Innovation Research Matching Grant from Montgomery County
Rockville, MD. Rise Therapeutics today announced that the Montgomery County Economic Development Fund’s subprogram, the SBIR/STTR Matching Grant Program, issued Rise Therapeutics a $25,000 matching grant to further their research project efforts in enhancing the effectiveness of immunotherapy in patients suffering from inflammatory bowel disease (IBD).
“We are immensely grateful for this support as we advance development of our R-3750 program,” Dr. Gary Fanger, President and CEO of Rise Therapeutics said. “Effective IBD treatments are critically needed, and we are excited to apply our expertise in immunotherapy to develop first-in-class medications for this difficult disease. We are heartened that our R-3750 program has such important support from the Montgomery County SBIR matching funds program.”
Over 3 million adults in the U.S. suffer from IBD, an umbrella term encompassing two chronic inflammatory diseases of the gastrointestinal tract: Crohn’s disease (CD) and ulcerative colitis (UC). IBD is typically diagnosed in the second or third decades of life; it is lifelong, and there is no cure. Current IBD treatments are systemic and can have serious side-effects. Novel therapies that are safe and effective, particularly in restoring the natural interaction between the immune system and gut microbiome, are needed and would be life-changing for patients.
Rise Therapeutics is an experienced oral therapeutics developer focused on launching promising products to the patients who need them the most. Rise Therapeutics has a robust oral immune therapeutics pipeline for which it is rapidly progressing into clinical studies.
About Rise Therapeutics
Rise Therapeutics is a privately held biotechnology company located in Rockville, Maryland. Rise is pioneering synthetic biology methodologies to develop novel cellular-based medicines. Rise Therapeutics leverages its unique and proprietary TriPartite X (TPX) approach to deliver targeted biologics orally, a novel step forward in the context of protein-based medicines. As a platform drug delivery approach, TPX is ideally suited to deliver any biological therapy orally and, in the context of Rise’s therapeutics product development interests, targeting immunology of the gut is a key breakthrough that gives Rise a competitive drug development advantage. Rise is currently focused on developing treatments for autoimmunity, inflammatory disease, infection, and cancer. These disease areas represent a large unmet need, both in the United States and around the world. For more information about Rise Therapeutics, please visit www.risetherapeutics.com.